Almirall receives the Fundamed-El Global award for Best Pharmaceutical Company of the Year

• The award recognises efforts to improve and modernise, excellent business activity and a commitment to research, society and its employees

• The winning company is chosen from all pharmaceutical, biotechnological and health technology companies operating in Spain

Madrid, 17 April 2007.- Almirall was presented with the award for Best Pharmaceutical Company of the Year at the sixth Fundamed-El Global Awards ceremony. The award recognises the company’s efforts to improve and modernise, its excellent business activity and its commitment to research, society and its employees.

The Fundamed Awards jury chooses the winning company directly, without pre- candidates, from all pharmaceutical, biotechnological and health technology companies operating in Spain.Fernando Puig de la Bellacasa, Assistant Secretary General for Health and Consumer Affairs, presented the award to Luciano Conde, Chief Operating Officer of Almirall.

The sixth edition of the awards saw fifty candidates in twelve different categories competing for recognition by the sector.As a new feature the event included two special mentions for best practices in Corporate Social Responsibility and All-time Medicine. In this category, Almax (almagate), Almirall’s proprietary R&D antacid, also won the award.

About Almirall

Almirall, a leading company committed to health, is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed drugs with the aim of improving people’s health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

Note

This document is a press release and not a prospectus. Investors should not therefore acquire or apply for any shares or other securities mentioned herein without having previously consulted the information contained within the official prospectus relating to the flotation of company shares on the Spanish stock exchanges, which will be published by the company in due course. Copies of the prospectus will be available at the registered offices of the Company once they have been published.

This document should in no way be construed as an offer or invitation to treat, nor does it represent an offer to buy or subscribe to shares in the Company. Likewise, the contents of this document and the fact that it has been distributed must not be used as, or form the basis for, any kind of contract or decision to invest and do not constitute any recommendation as regards the securities of the Company.

This communication is intended solely for people living outside the United Kingdom and may not be used by anybody living within that country.

The information contained herein does not constitute an offer of securities in the United States. Offers and sales of securities in the United States may not be made absent registration under the U.S. Securities Act of 1933, as amended, or an applicable exemption therefrom. This document does not solicit money, securities or any other type of consideration, and, if any money, securities or other type of consideration is sent in response hereto, it will not be accepted.

Finally, neither this document nor any copy thereof may be taken or transmitted to the United States of America, Canada, Australia or Japan or be distributed, either directly or indirectly, in the United States of America, Canada, Australia or Japan or given to residents of any of these countries.